USSTOCK.TODAY
Weekend. Closed Log in Sign up

Rein Therapeutics Inc(RNTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

RNTX
RNTX
Rein Therapeutics Inc
At close Nov 20 at 4:00 PM ET (Korea 11/21 06:00)
$0.34
-0.03 ▼ -8.38%
Nov 20 at 6:46 PM ET (Korea 11/21 08:46)
$0.39
+0.05 ▲ +15.76%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -1.57Insider Own ⓘ 8.49%Shs Outstand ⓘ 86.3MPerf Week ⓘ -38.98%
Market Cap ⓘ 0.03BForward P/E ⓘ -EPS next Y ⓘ -5.19%Insider Trans ⓘ 0.65%Shs Float ⓘ 79.0MPerf Month ⓘ -44.07%
Enterprise Value ⓘ 0.04BPEG ⓘ -EPS next Q ⓘ -0.1Inst Own ⓘ 49.18%Short Float ⓘ 0.9%Perf Quarter ⓘ -57.89%
Income ⓘ -0.05BP/S ⓘ -EPS this Y ⓘ 80.36%Inst Trans ⓘ 48.33%Short Ratio ⓘ 1.15Perf Half Y ⓘ -67.29%
Sales ⓘ 0.00BP/B ⓘ 3.74EPS next 5Y ⓘ 35.74%ROA ⓘ -87.89%Short Interest ⓘ 0.71MPerf YTD ⓘ -70.96%
Book/sh ⓘ 0.09P/C ⓘ 0.82EPS past 3/5Y ⓘ 31.21% 30.56%ROE ⓘ -100.48%52W High ⓘ -83.96% ($2.10)Perf Year ⓘ -75.59%
Cash/sh ⓘ 0.41P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -94.21%52W Low ⓘ 18.46% ($0.28)Perf 3Y ⓘ -82.17%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 40.47%Gross Margin ⓘ -Volatility(W/M) ⓘ 28.22% 15.39%Perf 5Y ⓘ -97.57%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.08Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 6.57EPS Q/Q ⓘ 70.38%Profit Margin ⓘ -RSI (14) ⓘ 24.71Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 6.57Sales Q/Q ⓘ -SMA20 ⓘ -40.54% ($0.57)Beta ⓘ 1.61Target Price ⓘ $6
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ 2026/11/16SMA50 ⓘ -49.33% ($0.67)Rel Volume ⓘ 1.09Prev Close ⓘ $0.37
Employees ⓘ 10LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ 40% -SMA200 ⓘ -65.61% ($0.99)Avg Volume(3M) ⓘ 0.61MPrice ⓘ $0.34
IPO ⓘ 2017/6/29Option/Short ⓘ No/YesTrades ⓘ 596Volume ⓘ 668,753Change ⓘ -8.38%
Company
RNTX RNTXRein Therapeutics Inc | NASD | Biotechnology Deep dive

A clinical-stage biopharmaceutical company developing novel drug candidates targeting rare lung diseases and fibrotic conditions. Headquartered in the United States, it is classified as a micro-cap biotech operating with a research-and-development focus, with no commercialized products yet. Pipeline progress serves as the central variable driving the company's valuation.

Quote

Over the past 1 year, on the lower side

84% below its 1-year high.

Now $0.34
52w low$0.2852w high$2.10
52W Range3%
Volume ⓘ 668,753

Traded about as much as usual. That is 109% of its average volume.

B
Overall · fairly good
We judged 6 of the 8 questions below. 3 rate excellent and 2 need caution.
No data for valuation, dividends, or not applicable.
ETFs holding this stock 4 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #439 of 598 in the industry

Based on market cap of $29M.

FAQ

FAQ

RNTX belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of RNTX is approximately $29M, ranking 5,003 within its sector.

RNTX has recorded a 52-week high of $2.10 and a low of $0.28.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels